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Thecontinuouseﬀortstoﬁndnewprognosticordiagnosticbiomarkershavestimulatedtheuseofmassspectrometry(MS)proﬁles
in a clinical setting. In the early days (about one decade ago), a single low-resolution mass spectrum derived from an individual’s
body ﬂuid was used for comparative studies. However, a peptide proﬁle of a complex mixture is most informative when recorded
on an ultrahigh resolution instrument such as a Fourier transform ion cyclotron resonance (FTICR) mass spectrometer. In this
study we show the beneﬁts of the ultrahigh resolving power and the high mass accuracy and precision provided by an FTICR mass
spectrometer equipped with a 15-tesla magnet. The ultrahigh-resolution data not only allow assignment of fragment ions with
high charge states (4+, 5+) but also enhance conﬁdence of human serum peptide identiﬁcations from tandem MS experiments.
This is exempliﬁed with collision-induced dissociation (CID) and electron transfer dissociation (ETD) data of middle-down-sized
endogenous or protein-breakdown peptides that are of interest in biomarker discovery studies.
1.Introduction
Mass spectrometry- (MS-) based proteomics is a principal
platform in systems biology, that is, the integrated approach
of diﬀerent technical disciplines to study the physiological
processes in a cell or tissue [1–3]. The diagnosis of a disease
ormonitoring new medicines ina (pre)clinicalsetting canbe
performed either through (theoretically) full proteome anal-
ysis or by molecular proﬁling of large cohorts of biological
samples. Nowadays, the ﬁrst approach is technically feasible,
howeveratlowthroughput[4].Inthelatterhigh-throughput
approach the relevant diﬀerences between numerous pep-
tides and proteins are mapped in aﬀected tissues or body
ﬂuids of healthy and diseased individuals [5, 6]. For this
purpose diﬀerential analyses of protein expression patterns
in cells, tissue, or body ﬂuids such as plasma or cerebrospinal
ﬂuid (CSF) are performed. These patterns can change as a
result of disease and are thus helpful in both early detection
andmonitoringthedevelopmentofthedisease.Additionally,
detection of biomarkers can also play a signiﬁcant role in
prevention. Proteomic approaches have been successfully
used to obtain information on the state of protein circuits
inside tumor cells and at the tumor-host interface [7].
Moreover, the analysis of peripheral blood (serum samples)
for biomarkers has emerged as a promising tool for cancer
diagnostics, disease monitoring, and prognostication of the
patient. Unfortunately, many biomarker discovery proﬁling
studies have not provided suﬃcient information on the
identity of the peptides or proteins of interest. One reason
for this incompleteness is the technical limitation of the used
MS-platform with respect to resolving power and MS/MS
capabilities. In this work we show the beneﬁts of using high-
end Fourier transform ion cyclotron resonance (FTICR) MS
for identiﬁcation of human serum peptides. These beneﬁts
are even more clear taking into account that many of these
peptides are endogenous or result from protein degradation.2 International Journal of Proteomics
1.1. Ultrahigh Resolution and- Precision Provided by FTICR.
It is well established that the sub-ppm mass accuracy of
fourier transform ion cyclotron resonance mass spectrom-
etry (FTICR-MS) improves the results and increases the con-
ﬁdence of identiﬁcations [8, 9]. Previously, we have shown
that a combination of highly standardized sample workup
protocols with FTICR precision proﬁles results in very low
mass measurement errors (MMEs) [9]. Moreover, FTICR-
MS is a powerful tool in tackling sample complexity due
to its ultrahigh mass resolution characteristics [10]. Several
recent instrumental and software developments (improved
electronicsandcomputertechnology)havemadeFTICR-MS
accessible to a broader research community, including the
life science area and the clinic. With suitable control and
proper calibration, high ﬁeld FTICR-MS routinely achieves
an MME lower than 1ppm [11, 12]. At very high ﬁelds,
such as in recently available 15-tesla instruments, MMEs at
a ppb level can be reached. The conﬁdence in peptide and
protein identiﬁcations improves signiﬁcantly with increasing
mass accuracy, especially if mass accuracies below 1ppm
are reached. Moreover, an increased mass accuracy assists
in the identiﬁcations of peptides that are not in a database
(e.g., unsequenced species, posttranslational modiﬁcations).
The potential of sub-ppm mass accuracy allows for in-
depth comparisons of complex peptide mixtures obtained
from patient and control body ﬂuids. In order to properly
use accurate mass values obtained from modern high-end
mass analyzers guidelines have been reported with respect to
statistical mass accuracy [13].
1.2.TandemMSUsingElectronTransferDissociation. Peptide
sequencing with electron transfer dissociation (ETD) MS/MS
h a sp r o v e nt ob ea ne x t r e m e l yp o w e r f u la n dc o m p l e m e n t a r y
tool next to the widely used collision-induced dissociation
(CID) [14, 15]. In a bottom-up proteomics workﬂow the
peptide sequence coverage is often improved with combined
CID and ETD fragmentation, either performed on-line in
an alternating way or oﬀ-line in a sequential experiment
[16, 17]. Initially, ETD was implemented on ion trap mass
spectrometers and this is still the most commonly applied
platform to perform peptide sequencing experiments. In the
ﬁeld of MS-based proteomics it is now well known that
ETD is especially favorable for sequencing larger peptides
with higher charge states (i.e., 3+, 4+), for middle-down
and top-down proteomics, and for determining the location
and identity of posttranslational modiﬁcations (PTMs) on
peptide backbones [15]. Recent developments have enabled
ETD experiments on ultrahigh-resolution mass analyzers
such as a time of ﬂight (TOF), Orbitrap, and FTICR [15, 18,
19]. In this work we will present both CID and ETD data
obtained from an FTICR system from middle-down-sized
peptides that are of interest in biomarker discovery studies.
2.MaterialsandMethods
2.1. Sample Collection and Serum Peptide Isolation. The
protocols for both the collection of human blood samples
and for serum peptide isolation have been described previ-
ously [9]. Informed consent was obtained from all patients
and the Leiden University Medical Center (LUMC) Medical
Ethical Committee approved the studies. Serum peptides
were isolated in a fully automated and standardized fash-
ion using reversed-phase (RP) C18-functionalized magnetic
beads. In this study, 10µL of commercially available RPC18
Dynabeads (Invitrogen, Carlsbad, CA, USA) was used for
the analysis of 5µL serum. The manufacturer’s protocol was
followed for the activation, wash, and desorption steps of the
RPC18 beads, with adjustments and optimizations to allow
implementation on a 96-channel liquid handling Hamilton
STAR plus pipetting robot [9].
2.2. ESI-FTICR-MS/MS. The eluates obtained from the
RPC18-magnetic bead workup were used for MS/MS exper-
iments (see sample collection). To this end, eluates from
96 diﬀerent samples were pooled and ultraﬁltrated using
a 30kDa ﬁlter (Amicon Ultra 0.5mL; Millipore). The
ﬁltrate was concentrated by lyophilization before RPC18-LC-
MS analysis on a splitless nanoLC-Ultra 2D plus system
(Eksigent, Dublin, CA USA) equipped with a PepMap
C18 trap column (300 micrometer internal diameter, 5
millimeter length; Dionex, Sunnyvale, CA USA) and a
ChromXP C18-analytical column (300 micrometer internal
diameter, 15 centimeter length; Eksigent). Here, one minute
manual fraction collection was performed at a ﬂow rate
of 4 microliter per minute, with a gradient of 4% to
44% acetonitril in 0.05% formic acid buﬀer. Then, the
35 fractions were analysed using a Bruker 15 tesla solariX
FTICR mass spectrometer equipped with a CombiSource, a
quadrupole for precursor ion selection, a hexapole collision
cell for CID, and an ETD source on a splitted octopole
after mixing them with 100 microliter of spray solution
(50/50 MeOH/H2O 0.1% formic acid) [9]. Direct infusion
electrospray ionisation (ESI) experiments were carried out at
an infusion rate of 2 microliter per minute. The ion funnels
were operated at 100V and 6.0V, respectively, with the
skimmers at 15V and 5V. The trapping potentials were set
at 0.60V and 0.55V, the analyzer entrance was maintained at
–7V, and side kick technology was used to further optimize
peak shape and signal intensity. The required excitation
power was 28% with a pulse time of 20.0µs. MS/MS
experiments were performed with the Q at an isolation
window of 10 mass units, followed by either CID or ETD
and fragment ion mass analysis in the ICR cell. For CID
experiments, both the collision energy and the accumulation
time in the hexapole collision cell were optimized for each
precursor ion. Collision energies varied from 5 to 33V while
the accumulation times varied from 1 to 5 seconds. For ETD
experiments the ETD reagent accumulation time was ﬁxed
at 400 milliseconds (ﬂuoranthene from negative chemical
ionization (NCI) source). The ETD spectrum was optimized
by varying the reaction time (from 10 to 100 milliseconds,
with an optimum at 50 milliseconds), varying the peptide
(analyte) accumulation time (depending on the precursor
ion intensity), and modifying the mirror RF amplitude
(280−300Vpp).International Journal of Proteomics 3
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Figure 1: ESI-FTICR-MS/MS spectra of an albumin peptide isolated from a human serum sample, with sequence coverage in CID (a) and
ETD (b).4 International Journal of Proteomics
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Figure 2: ESI-FTICR-MS/MS spectra of a prothrombin peptide isolated from a human serum sample, with sequence coverage in CID (a)
and ETD (b). In order to exemplify the ultrahigh resolving power of the system the insets show the isotopic patterns of fragment ions at m/z
793 [y34(5+)] and at m/z 1028 [y35(4+)].International Journal of Proteomics 5
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Figure 3: Summary of mass measurement errors of fragment ions in ESI-FTICR-MS/MS CID (a) and ETD (b) spectra of a prothrombin
peptide isolated from a human serum sample.
2.3. Data Analysis. It should be noted that the peptides that
were sequenced in this work (obtained from human serum
samples) were either endogenous peptides or breakdown
products from serum proteins. This implies that any amino
acid can be present at the C- and the N-terminus. As a
consequence,theinterpretation ofMS/MSspectrawaspartly
performed manually (de novo) and partly using software
from Bruker Daltonics (Data Analysis, BioTools). With a
manually determined part of the sequence (sequence tag)
a BLAST search was performed. These results were further
used to match other parts of the MS/MS data.
3. Results andDiscussion
Matrix-assisted laser desorption ionization (MALDI) preci-
sion proﬁles of serum eluates were obtained using a state-
of-the-art solariX-FTICR system equipped with a 15-tesla
magnet [9]. Since the purpose of this study is to report
peptide identiﬁcations, the discussion of such precision
proﬁles is outside the scope of this work. Nevertheless, it
should be emphasized that the accurate mass list of peptides
obtainedfromprecisionproﬁlesallowedawindowofoverlap
between species observed in MALDI proﬁles and those
determined in ESI spectra lower than 1ppm. For a complex
mixturesuchasserumpeptidesthiscanonlybeachievedina
single-stepanalysis(i.e.,withouttheneedforLC-separation)
using the ultrahigh resolving power of FTICR.
The solariX-FTICR system was further used to perform
MS/MS experiments aiming for peptide sequencing. To
this end, peptide mixtures were directly infused in ESI
mode, isolated in the Q, and fragmented through either
CID or ETD. These peptide mixtures were obtained after
suitable sample clean-up from the magnetic bead eluates
and fractionation (as described in Section 2). As an example,
the CID and ETD spectra of an albumin fragment (UniProt
P02768,number25–48)areshowninFigure 1.Theultrahigh
resolving power of the FTICR allowed conﬁdent assignment
of many fragment ions, resulting in a peptide sequence
coverage of 87% (20 out of 23 peptide bonds) and 91% from
CID and ETD, respectively. From Figure 1 is follows that in
the albumin peptide three bond cleavages were not observed
uponCID,namely,betweentheaminoacidsS-E,H-R,andF-
K. In the ETD spectrum these bond cleavages, among others,
were observed, stressing the complementarity of these two
fragmentation methods. The complementarity is also valid
vice versa; namely, bond cleavages between amino acids E-E
andK-AwereobservedinCIDandnotinETD.Furthermore,
it is interesting to report on the signal intensities of the
CID and ETD fragments of the peptide with MW 2754Da:
these varied from 4 × 10E6t o4× 10E8, with a precursor
ion intensity of 5 × 10E8, and from 1 × 10E7t o3× 10E8,
with a precursor ion intensity of 3 × 10E9, respectively. This
exempliﬁes the large dynamic range of the FTICR; that is,
also the low abundant fragment ions are clearly detectable in
an MS/MS spectrum.
The second example of complementarity of CID and
ETD fragmentation is presented in Figure 2, although not
up to a total sequence coverage of 100%. The sequence
coverage of the prothrombin peptide was 77% from the
CID spectrum and 60% from the ETD-spectrum, whereas
the combination of data resulted in 89%. This peptide
was identiﬁed as a fragment from prothrombin (UniProt
P00734, number 328–363), namely, TFGSGEADC(C)GLR-
PLFEKKSLEDKTERELLESYIDGR. Note that this peptide
contains a cysteinylation at cysteine 336 (indicated between
parentheses) that originates from the disulﬁde bridge to
cysteine482.Boththeultrahighresolvingpowerandthesub-
ppm MMEs of all fragmentions providedby theFTICRwere
essential for conﬁdent assignments. In the case of the CID
spectrum especially, the charge states of most fragment ions
obtained from the large precursor peptide with ﬁve protons
could not have been resolved with relatively low-resolution
instrumentation such as an ion trap mass spectrometer. This
is exempliﬁed by the insets in Figure 2, showing the isotopic
patterns of fragment ions at m/z 793 [y34(5+)] and at m/z
1028 [y35(4+)]. The MMEs are overviewed in Figure 3.
The average MMEs for the CID and ETD experiments of
the peptide with MW 4210Da were 0.01 ± 0.16ppm and
−0.03 ± 0.19ppm, respectively. Again, the beneﬁts of the
large dynamic range (more than two orders of magnitude)
of detecting fragment ions become clear from the following6 International Journal of Proteomics
number: the signal intensities of the CID fragments of the
peptidewithMW4210Davariedfrom2.5×10E6to5×10E8,
with a precursor ion intensity of 2 × 10E8, and the signal
intensities of the ETD fragments of this peptide varied from
1 × 10E7t o6× 10E8, with a precursor ion intensity of
8 ×10E9.
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